Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease
Background: Recombinant human erythropoietin (rHuEPO) is an effective treatment for renal anemia. Recently, there is evidence to suggest that rHuEPO may reduce podocyte injury in diabetic kidney disease (DKD). However, there is no published study on the change in podocyte injury marker levels before...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co. Ltd.
2023-01-01
|
| Series: | Advances in Biomarker Sciences and Technology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2543106423000066 |
| _version_ | 1797291712529301504 |
|---|---|
| author | Lingfeng Zeng Jack Kit-Chung Ng Winston Wing-Shing Fung Gordon Chun-Kau Chan Kai-Ming Chow Cheuk-Chun Szeto |
| author_facet | Lingfeng Zeng Jack Kit-Chung Ng Winston Wing-Shing Fung Gordon Chun-Kau Chan Kai-Ming Chow Cheuk-Chun Szeto |
| author_sort | Lingfeng Zeng |
| collection | DOAJ |
| description | Background: Recombinant human erythropoietin (rHuEPO) is an effective treatment for renal anemia. Recently, there is evidence to suggest that rHuEPO may reduce podocyte injury in diabetic kidney disease (DKD). However, there is no published study on the change in podocyte injury marker levels before and after rHuEPO treatment in DKD. Methods: We measured serum nephrin and podocalyxin level, and their corresponding plasma mRNA levels, in 49 DKD patients before rHuEPO treatment, and then 12 and 36 weeks afterward. Results: There were reductions in serum nephrin (p = 0.002) and podocalyxin levels (p = 0.09), as well as their corresponding plasma mRNA levels (p < 0.0001 for both) after rHuEPO treatment. The change in serum nephrin and podocin level had significant inverse correlation with the concomitant change in hemoglobin level (r = −0.670 and −0.739 respectively, p < 0.0001 for both), but not with the change in kidney function or proteinuria. Conclusion: Serum nephrin and podocalyxin levels and their corresponding plasma mRNA levels were significant reduced after rHuEPO treatment in DKD patients, and the change in serum nephrin and podocalyxin levels correlated with the change in hemoglobin level. The effect of rHuEPO on podocyte injury deserves further study. |
| first_indexed | 2024-03-07T19:41:42Z |
| format | Article |
| id | doaj.art-920afa81d83d400596304043f2a9ad88 |
| institution | Directory Open Access Journal |
| issn | 2543-1064 |
| language | English |
| last_indexed | 2024-03-07T19:41:42Z |
| publishDate | 2023-01-01 |
| publisher | KeAi Communications Co. Ltd. |
| record_format | Article |
| series | Advances in Biomarker Sciences and Technology |
| spelling | doaj.art-920afa81d83d400596304043f2a9ad882024-02-29T05:20:13ZengKeAi Communications Co. Ltd.Advances in Biomarker Sciences and Technology2543-10642023-01-0155056Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney diseaseLingfeng Zeng0Jack Kit-Chung Ng1Winston Wing-Shing Fung2Gordon Chun-Kau Chan3Kai-Ming Chow4Cheuk-Chun Szeto5Carol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, China; Li Ka Shing Institute of Health Sciences (LiHS), Faculty of Medicine, the Chinese University of Hong Kong, Shatin, Hong Kong, ChinaCarol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, ChinaCarol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, ChinaCarol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, ChinaCarol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, ChinaCarol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, China; Li Ka Shing Institute of Health Sciences (LiHS), Faculty of Medicine, the Chinese University of Hong Kong, Shatin, Hong Kong, China; Corresponding author. Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China.Background: Recombinant human erythropoietin (rHuEPO) is an effective treatment for renal anemia. Recently, there is evidence to suggest that rHuEPO may reduce podocyte injury in diabetic kidney disease (DKD). However, there is no published study on the change in podocyte injury marker levels before and after rHuEPO treatment in DKD. Methods: We measured serum nephrin and podocalyxin level, and their corresponding plasma mRNA levels, in 49 DKD patients before rHuEPO treatment, and then 12 and 36 weeks afterward. Results: There were reductions in serum nephrin (p = 0.002) and podocalyxin levels (p = 0.09), as well as their corresponding plasma mRNA levels (p < 0.0001 for both) after rHuEPO treatment. The change in serum nephrin and podocin level had significant inverse correlation with the concomitant change in hemoglobin level (r = −0.670 and −0.739 respectively, p < 0.0001 for both), but not with the change in kidney function or proteinuria. Conclusion: Serum nephrin and podocalyxin levels and their corresponding plasma mRNA levels were significant reduced after rHuEPO treatment in DKD patients, and the change in serum nephrin and podocalyxin levels correlated with the change in hemoglobin level. The effect of rHuEPO on podocyte injury deserves further study.http://www.sciencedirect.com/science/article/pii/S2543106423000066PodocyteProteinuriaChronic kidney diseaseAnemia |
| spellingShingle | Lingfeng Zeng Jack Kit-Chung Ng Winston Wing-Shing Fung Gordon Chun-Kau Chan Kai-Ming Chow Cheuk-Chun Szeto Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease Advances in Biomarker Sciences and Technology Podocyte Proteinuria Chronic kidney disease Anemia |
| title | Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease |
| title_full | Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease |
| title_fullStr | Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease |
| title_full_unstemmed | Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease |
| title_short | Recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease |
| title_sort | recombinant erythropoietin treatment improves serum podocyte marker levels in diabetic kidney disease |
| topic | Podocyte Proteinuria Chronic kidney disease Anemia |
| url | http://www.sciencedirect.com/science/article/pii/S2543106423000066 |
| work_keys_str_mv | AT lingfengzeng recombinanterythropoietintreatmentimprovesserumpodocytemarkerlevelsindiabetickidneydisease AT jackkitchungng recombinanterythropoietintreatmentimprovesserumpodocytemarkerlevelsindiabetickidneydisease AT winstonwingshingfung recombinanterythropoietintreatmentimprovesserumpodocytemarkerlevelsindiabetickidneydisease AT gordonchunkauchan recombinanterythropoietintreatmentimprovesserumpodocytemarkerlevelsindiabetickidneydisease AT kaimingchow recombinanterythropoietintreatmentimprovesserumpodocytemarkerlevelsindiabetickidneydisease AT cheukchunszeto recombinanterythropoietintreatmentimprovesserumpodocytemarkerlevelsindiabetickidneydisease |